The epithelial sodium channel in hypertension

Current Hypertension Reports

Volumn 1, Issue 2, 1999, Pages 158-163

  Warnock, David G ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL SODIUM CHANNEL; MINERALOCORTICOID; SCNN1B PROTEIN, HUMAN; SODIUM CHANNEL;

BLOOD; GENETIC POLYMORPHISM; GENETICS; HUMAN; HYPERTENSION; MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

EPITHELIAL SODIUM CHANNEL; HUMANS; HYPERTENSION; MINERALOCORTICOIDS; MUTATION; POLYMORPHISM, GENETIC; SODIUM CHANNELS;

EID: 0033108030     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-999-0013-x     Document Type: Article

References (43)

1. Liddle GW, Bledsoe T, Coppage WS: A familial renal disorder simulating primary aldosteronism but with negligible aldosterone secretion. Trans Am Assoc Physicians 1963, 76:199-213.
2. Botero-Velez M, Curtis JJ, Warnock DG: Brief report: Liddle's syndrome revisited. N Engl J Med 1994, 330:178-181.
3. Warnock DG: Liddle syndrome: an autosomal dominant form of human hypertension. Kidney Intern 1998, 53:18-24. Detailed description of the clinical presentation and pathophysiologic basis for pseudoaldosteronism.
4. Rossier BC: Cum grano salis: the epithelial sodium channel and the control of blood pressure. J Amer Soc Nephrol 1997, 8:980-992. Homer Smith Lecture describing the expression cloning of ENaC and the genetic disorders of its regulation.
5. Shimkets RA, Warnock DG, Bositis CM, et al.: Liddle's syndrome: heritable human hypertension caused by mutations in the b subunit of the epithelial sodium channel. Cell 1994, 79:407-414.
6. Schild L, Lu Y, Gautschi I, et al.: Identification of a PY motif in the epithelial Na channel subunits as a target sequence for mutations causing channel activation found in Liddle's syndrome. EMBO J 1996, 15:2381-2387.
7. Staub O, Dho S, Henry PC, et al.: WW domains of Nedd4 bind to the proline-rich PY motifs in the epithelial Na+ channel deleted in Liddle's syndrome. EMBO J 1996, 15:2371-2380.
8. Staub O, Gautschi I, Ishikawa T, et al.: Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination. EMBO J 1997, 16:6325-6336. Cell biologic description of one pathway by which the expression of ENaC is controlled at the plasma membrane level.
9. Snyder PM, Price M, McDonald FJ, et al.: Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial Na+ channel. Cell 1995, 83:969-978.
10. Firsov D, Schild L, Gautschi I, et al.: Cell surface expression of the epithelial Na channel and a mutatant causing Liddle syndrome: a quantitative approach. Proc Natl Acad Sci USA 1996, 93:15370-15375.
11. Shimkets RA, Lifton RP, Canessa CM: The activity of the epithelial sodium channel is regulated by clathrin-mediated endocytosis. J Biol Chem 1997, 272:25537-25541.
12. Shackleton CH: Mass spectrometry in the diagnosis of steroidrelated disorders and in hypertension research. J Steroid Biochem Molec Biol 1993, 45:127-140.
13. Su YR, Rutkowski MP, Klanke CA, et al.: novel variant of the ßsubunit of the amiloride-sensitive sodium channel in African Americans. J Am Soc Nephrol 1996, 7:2543-2549.
14. Baker EH, Dong YB, Sagnella GA, et al.: Association of hypertension with T594M mutation in the b subunit of epithelial sodium channels in black people resident in London. Lancet 1998, 351:1388-1392. Provocative report of polymorphisms in the ENaC beta subunit, and a genetic association to hypertension in blacks.
15. Chang SS, Grunder S, Hanukoglu A, et al.: Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 1996, 12:248-253.
16. Strautnieks SS, Thompson RJ, Gardiner R. M, et al.: A novel splice-site mutation in the gamma subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type 1 families. Nat Genet 1996, 13:248-250.
17. Geller DS, Rodriquez-Soriano J, Boado AV, et al.: Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohypoaldosteronism, type I. Nat Genet 1998, 19:279-281. Authoritative distinction between the dominant and recessive forms of pseudohypoaldosteronism, type I.
18. Hanukoglu A, Joy O, Steinitz M, et al.: Pseudohypoaldosteronism due to renal and multisystem resistance to mineralocorticoids respond differently to carbenoxolone. J Steroid Biochem Molec Biol 1997, 60:105-112.
19. Wilson RC, Krozowski ZS, Li K, et al.: A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1995, 80:2263-2266.
20. Mune T, Rogerson FM, Nikkila H, et al.: Human hypertension caused by mutations in the kidney isozyme of 11 betahydroxysteroid dehydrogenase. Nat Genet 1995, 10:394-399.
21. Walker BR, Campbell JC, Fraser R, et al.: Mineralocorticoid excess and inhibition of 11b-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol 1992, 37:483-492.
22. Funder JW, Pearce PT, Smith AT: Mineralocorticoid action: target tissue specificity is enzyme, not receptor mediated. Science 1987, 242:583-585.
23. Stewart PM, Valentino R, Wallace AM, et al.: Mineralocorticoid activity of liquorice: 11b-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987, 2:821-824.
24. Edwards DJ, Bernier SM: Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. Life Sci 1996, 59:1025-1030.
25. Lee YS, Lorenzo BJ, Koufis T, et al.: Grapefruit juice and its flavinoids inhibit 11b-hydroxysteroid dehydrogenase. Clin Pharmacol Ther 1996, 59:62-71.
26. Stewart PM, Atherden SM, Shearing CH, et al.: Mineralocorticoid activity of carbenoxolone: contrasting effects of carbenoxolone and liquorice on 11b-hydroxysteroid dehydrogenase activity in man. Clin Sci 1990, 78:49-54.
27. Ingram MC, Wallace AM, Collier A, et al.: Sodium status, corticosteroid metabolism and blood pressure in normal human subjects and in a patient with abnormal salt appetite. Clin Exp Pharmacol Physiol 1996, 23:375-378.
28. Walker BR, Stewart PM, Shackleton CHL, et al.: Deficient inactivation of cortisol by 11b-hydroxysteroid dehydrogenase in essential hypertension. Clin Endocrinol 1993, 39:221-227.
29. Soro A, Ingram MC, Tonolo G, et al.: Evidence of coexisting changes in 11b-hydroxysteroid dehydrogenase and 5b reductase activity in subjects with untreated essential hypertension. Hypertension 1995, 25:67-70.
30. Dick B, Sharma AM Schorr U, et al.: Salt-sensitivity is associated with impaired 11b-hydroxy-steroid dehydrogenase type 2 activity in humans [abstract]. J Am Soc Nephrol 1998, 9:322. Preliminary report suggesting that there may be a genetic association between salt-sensitive hypertension and human 11b-hydroxy-steroid dehydrogenase, type 2 activity.
31. Smolenicka Z, Bach E, Schaer A, et al.: A new polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene. J Clin Endocrinol Metab 1998, 83:1814-1817. Simple bi-allelic polymorphism in an important candidate gene in human low renin hypertension.
32. Watson BJ, Bergman SM, Myracle A, et al.: Genetic Association of 11 beta-hydroxysteroid dehydrogenase type 2(HSD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension 1996, 28:478-482. Flanking microsatellites and allelic frequencies for an important candidate gene in blacks with low renin hypertension.
33. Lifton RP, Dluhy RG, Powers M, et al.: Hereditary hypertension caused by chimeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 1992, 2:66-74.
34. Lifton RP, Dluhy RG, Powers M, et al.: A chimaeric 11 b-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262-265.
35. Pascoe L, Jeunemaitre X, Lebrethon M-C, et al.: Glucocorticoidsuppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree. J Clin Invest 1995, 96:2236-2246.
36. Rich G, Ulick S, Cook S, et al.: Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype. Ann Int Med 1992, 116:813-820.
37. Connell JMC, Jamieson AJ, Davies E, et al.: 11b-hydroxylase activity in glucocorticoid suppressible hyperaldosteronism: lessons for essential hypertension. Endocrinol Res 1996, 22:691-700.
38. White PC: Inherited forms of mineralocorticoid hypertension. Hypertension 1996, 28:927-936.
39. Komiya I, Yamada T, Aizawa T, et al.: Inappropriate elevation of the aldosterone/plasma renin activity ratio in hypertensive patients and 18-hydroxy-11-deoxycorticosterone: a subtype of essential hypertension? Cardiology 1991, 78:99-110.
40. Lifton RP: Molecular genetics of human blood pressure variation. Science 1996, 272:676-680.
41. Fardella CE, Miller WL: Molecular biology of mineralocorticoid metabolism. Ann Rev Nutr 1996, 16:443-470.
42. Holland OB: Primary aldosteronism. Semin Nephrol 1995, 15:116-125.
43. Jamieson A, Ingram, MC, Inglis, GC, et al.: Altered 11b-hydroxylase activity in glucocorticoid-suppressible hyperaldosteronism. J Clin Endocrinol Metab 1996, 81:2298-2302.